You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
|
|---|---|
| Published in |
Journal of Hematology & Oncology, October 2021
|
| DOI | 10.1186/s13045-021-01188-x |
| Pubmed ID | |
| Authors |
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 30% |
| Spain | 1 | 10% |
| Unknown | 6 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Scientists | 2 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 11% |
| Other | 5 | 9% |
| Researcher | 4 | 7% |
| Student > Doctoral Student | 2 | 4% |
| Student > Ph. D. Student | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 30 | 55% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 22% |
| Biochemistry, Genetics and Molecular Biology | 6 | 11% |
| Nursing and Health Professions | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Mathematics | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 31 | 56% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#1,946,431
of 25,463,724 outputs
Outputs from Journal of Hematology & Oncology
#153
of 1,295 outputs
Outputs of similar age
#44,550
of 443,091 outputs
Outputs of similar age from Journal of Hematology & Oncology
#9
of 54 outputs
Altmetric has tracked 25,463,724 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,295 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,091 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.